Key Takeaways
- Ecovia Bio has closed a Series B funding round led by Pointe Angels.
- The funding will support expansion of manufacturing capacity at the company’s Livonia, Michigan facility.
- The company produces gamma polyglutamic acid (γ-PGA) biopolymers for cosmetics, agriculture, hygiene, and personal care.
- The company expects its Livonia facility to reach full operational capacity by 2028.
- Additional production sites are under evaluation to support long-term global demand.
Ecovia Bio Secures Series B Funding for Capacity Expansion
Ecovia Bio, a biotechnology company focused on biopolymer ingredients, announced the closing of a Series B funding round led by Pointe Angels, an independent angel investor group based in Michigan. The investment will be used to expand manufacturing capacity at Ecovia Bio’s Livonia facility in response to growing demand for its AzuraBase and AzuraGel product lines.
The company’s products are based on gamma polyglutamic acid (γ-PGA), a biodegradable biopolymer used across cosmetics, personal care, agriculture, and hygiene applications. According to Ecovia Bio, the expansion will support both near-term customer needs and longer-term supply commitments.
“We are excited to partner with Pointe Angels,” said Kousay Said, Chief Executive Officer of Ecovia Bio. “This capital enables us to meet immediate demand from our cosmetics, personal care, and agricultural customers while establishing the infrastructure needed to serve the hygiene sector at industrial scale.”
Ecovia Bio Manufacturing Expansion and Market Demand
Scaling Production at the Livonia Facility
The Series B funding will finance a comprehensive expansion program at the company's Livonia manufacturing site. The company stated that the facility is expected to reach full operational capacity by 2028. In parallel, the company has begun evaluating additional production locations to support demand beyond that timeframe and strengthen supply chain resilience.
Ecovia Bio positions its γ-PGA-based materials as alternatives to petrochemical-derived polymers used in consumer and industrial products. The company noted that increasing production capacity is central to supporting customers across multiple high-growth markets.
Addressing Environmental and Regulatory Pressures
Focus on Biodegradable Alternatives
Ecovia Bio’s products are designed to reduce reliance on synthetic polymers commonly used in hygiene, cosmetic, and agricultural formulations. The company stated that its biopolymers are intended to meet performance requirements while aligning with evolving regulatory standards and customer preferences for bio-based materials.
By expanding its manufacturing footprint, the company aims to serve manufacturers seeking scalable alternatives to conventional superabsorbent and specialty polymers.
Investor Perspective and Outlook For Ecovia Bio
David Bloom, Executive Director of Pointe Angels, highlighted the company’s commercial progress and operational planning.
“Ecovia Bio represents exactly the kind of venture we look to support,” Bloom said. “The company has demonstrated the ability to produce γ-PGA at commercial scale and serve multiple end markets from a single manufacturing platform. We believe this expansion positions the business for continued growth.”
Ecovia Bio stated that the Series B round strengthens its ability to support global customers while maintaining Michigan as its manufacturing base.
